Havas Health & You announced a strategic partnership with Trinity Life Sciences, a healthcare-focused consulting firm, Tuesday afternoon at the J.P. Morgan Healthcare Conference.

HH&Y stated that the partnership will allow both companies to “offer cohesive end-to-end commercial solutions to the life sciences industry.” As part of the deal, the 2022 MM+M Agency 100 honoree is taking a minority stake in Trinity.

The move is the first major news unveiled by HH&Y in 2023 following a busy 2022.

In December, the company announced a global partnership with Evermed, an HCP engagement company, to expand its content solutions for doctors and other clinical workers. Earlier in the year, HH&Y teamed with Republica Havas to launch Republica Havas Health.

HH&Y also made a series of leadership changes throughout the year, including naming Paul Kinsella as chief creative officer of HH&Y Europe, Paul Pfleiderer as president of Havas Life New York, Laura Mizrahi as CCO at its flagship H4B Chelsea agency and Elizabeth Egan as CEO of HH&Y Europe.

“The rapid and dynamic pace of the life sciences industry requires we take a more comprehensive view to move smarter and faster. The combination of Trinity and Havas Health & You provides truly best in class expertise and capabilities through all stages of the pre-commercial and commercial lifecycle,” said Donna Murphy, Global CEO of Havas Creative Group and HH&Y. “Modern technologies are helping to fuel incredible innovations in health, and this brings new challenges — this partnership enables us to best meet the industry’s needs.”

For Trinity, the HH&Y partnership follows its acquisition of D Cube Analytics, a data science and analytics provider, in 2022. The company also partnered with Bain & Co. last year as well.

“When we started to talk about the potential partnership, it became clear that both Trinity and Havas Health & You had missions that were solidly aligned. Both companies know every decision impacts a life, and it is what gets us up in the morning,” Trinity Life Sciences CEO David Fitzhenry said in a statement. “To layer on sophisticated data, insights and analytics to branding and communications programs for our collective life science clients will be industry-changing. Addressing key areas such as launch, customer experience and application of technologies to advance omnichannel will be our focus.”